Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
10 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 November and 9 November 2023 Download
03 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 27 October and 2 November 2023 Download
27 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 20 October and 26 October 2023 Download
20 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 13 October and 19 October 2023 Download
13 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 6 October and 12 October 2023 Download

Pages

Date Title Description PDF
08 May 2019 Information on P&L ROVI releases the first quarter 2019 results presentation Download
08 May 2019 Information on P&L ROVI releases the press release related to the first quarter 2019 financial results Download
07 May 2019 Liquidity contracts and specialists ROVI announces the signature of a new liquidity contract with Renta 4 Banco, S.A.     Download
30 Apr 2019 Liquidity contracts and specialists ROVI announces the termination of the liquidity contract signed with JB Capital Markets, S.V., S.A.U.     Download
11 Apr 2019 Strategic agreements with third parties The Company releases the press release related to the marketing agreement of Tetridar® in Spain   Download

Pages